Interestingly, FAM134B was identified to be significantly downregulated in HCC who revised radiotherapy and exhibit stable disease (SD) or progressive disease (PD), compared with patient’s exhibit (PD) complete response (CR) or partial response (PR) (n = 7; P < 0.001; TCAG- hepatocellular carcinoma; Fig. 1B). Here, RETREG1 is linked to hepatocellular carcinoma.